© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Liver Meeting 2014
Click Here for More Conferences
Click Here for AASLD.org
An Introduction to Hepatitis

Viread Effectively Combats Hepatitis B for at Least 8 Years

Viread (tenofovir) is highly effective at suppressing hepatitis B, even after an eight-year period.

Lower Hep C Risk for Young IDUs on Opioid Maintenance Therapy

Taking opioid maintenance therapy with methadone or buprenorphine is linked to a 61 percent reduced risk of hepatitis C virus (HCV) among youn...

Harvoni Cures High Rates of People With Genotype 4 of Hep C

Gilead Sciences’ newly approved Harvoni (ledipasvir/sofosbuvir) cured nearly all people with genotype 4 of hepatitis C in a small trial.

Sovaldi-Based Hep C Regimens Work Well in the Real World

Hepatitis C treatments based on Gilead Sciences’ Sovaldi (sofosbuvir) are faring just as well in the real world as in clinical trials.

Gilead’s 8-Week Hep C Cure Is Good for Genotype 3, Not 1 or 2

Eight weeks of Sovaldi and GS-5816, with or without ribavirin, cured high rates of people with genotype 3 of hepatitis C, but yielded unsatisf...

AbbVie’s ’3D’ Regimen Plus Ribavirin Cures All With Hep C Genotype 4

AbbVie’s ’3D’ regimen plus ribavirin cured all people with genotype 4 of hepatitis C in a recent trial, plus 91 percent of those with genotype...

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
Hepatitis A: The Basics

Interferon Raises Chance of HBsAg Loss in People With Hepatitis B

Adding interferon to Viread (tenofovir) treatment for hepatitis B virus raised the likelihood of hep B surface antigen (HBsAg) loss in an ongo...

Harvoni Cures Almost All People With Hep C Coinfected With HIV

Twelve weeks of Gilead Sciences newly approved Harvoni cured nearly all people with genotype 1 of hepatitis C who were coinfected with HIV in...

12 Weeks of Harvoni and Ribavirin Cures 96% of Cirrhotics With HCV

Twelve weeks of Harvoni plus ribavirin cured nearly all highly treatment-experienced cirrhotic people with genotype 1 of hepatitis C virus.

Sovaldi and Olysio Cure High Rates of Hep C Post-Liver Transplant

Sovaldi (sofosbuvir) and Olysio (simeprevir), with or without ribavirin, cures over 90 percent of people with hepatitis C who have had a liver...

High Post-Liver Transplant Survival Rates for People With HIV

HIV-positive people who have liver transplants because of liver cancer have high survival rates.

Hot topics

Forums: Support and discussion
Blogs: The community speaks

Harvoni Posts Good Cure Rates for Hepatitis Genotypes 3 and 6

Twelve weeks of Gilead Sciences’ Harvoni cured high rates of genotypes 3 and 6 of hepatitis C virus, with and without ribavirin.

U.S. Vets Have Low Rates of Hep B Testing and Treatment

Americans receiving care through the VA are infrequently tested for hepatitis B, and only a fraction of those who test positive are treated or...

Excellent Results for 12 and 18 Weeks of Merck’s Dual Hep C Regimen

Twelve or 18 weeks of Merck?s grazoprevir/elbasvir, with or without ribavirin, cured 91 to 100 percent of hard-to-treat people with genotype 1...

4 Weeks of Merck’s Hep C Meds Plus Sovaldi Fails; 8 Weeks Does Well

Four weeks of Merck’s grazoprevir/elbasvir plus Gilead’s Sovaldi posted poor interim results in treating people with geno 1 of hepatitis C

Hep C Cure Lowers Risk of Death, Liver Cancer and Transplants

Achieving a cure for hepatitis C through interferon-based treatment reduces the risk of death, liver cancer and needing a liver transplant.
Advertisement
Science News
Newsfeed
Features
Ask Hep